Fig. 8

Tanshinone IIA positively regulates adriamycin sensitivity by suppressing breast cancer stemness. A MiR-125b and STARD13 levels were detected in MCF-7-Adr and MCF-7 cells. B MiR-125b and STARD13 levels were examined in Tanshinone IIA-MCF-7-Adr cells or not. C MCF-7-Adr cells were treated with adriamycin (2 μM) as well as Tanshinone IIA (10 μM), after 24 h, 48 h and 72 h, cell viability was evaluated by MTT assay. D Ki67 mRNA level was determined in cells depicted in C with 48 h treatment. E Protein levels of Ki67 and apoptotic executor (Cleaved PARP) were examined in D-described cells. F Cell viability was evaluated in MCF-7 cells with adriamycin (2 μM) as well as Tanshinone IIA (10 μM) treatment or not. G Ki67 mRNA level was measured in F-depicted cells. H Protein levels of Ki67 and apoptotic executor (Cleaved PARP) were examined in E-depicted cells. **p < 0.01 vs. Control, ^##p < 0. 01 vs. MCF-7-Adr + Adriamycin + Tanshinone IIA group, n = 3